Epigenetic Biomarker Discovery in HPV related HNSCC

描述(申请人提供)：高危人乳头瘤病毒相关头颈部鳞状细胞癌(HPVHNSCC)的发病率正在迅速增加，并将很快超过美国的宫颈癌发病率。目前还没有有效的方法来检测临床前或早期的HPVHNSCC，筛选HPVHNSCC发展的高危人群，甚至没有检测治疗后HPVHNSCC的微观持久性。然而，在癌前和早期癌症的体液中检测到了表观遗传学改变，多重检测显示出鉴定口腔癌前病变患者的希望。我们的基本假设是，基于HPVHNSCC特异性表观遗传学改变的血浆和唾液的多重检测，结合高危HPV DNA的存在，有可能作为HPVHNSCC存在的有用测试。该项目将作为HPVHNSCC检测的发现和诊断验证生物标记物开发试验，潜在地应用于评估疾病反应和开发基于人群的筛查测试。

DESCRIPTION (provided by applicant): High risk human papilloma virus related head and neck squamous cell carcinoma (HPVHNSCC) incidence is rapidly increasing, and will soon surpass the incidence of cervical carcinoma in the US. There are no effective ways to detect preclinical or early HPVHNSCC, screen populations at increased risk for HPVHNSCC development, or even assay for microscopic persistence of HPVHNSCC after therapy. However, epigenetic alterations have been detected in body fluids from premalignant and early stage cancers and multiplex tests have shown promise for identification of patients with oral premalignancy. Our primary hypothesis is that multiplex testing of plasma and salivary rinses based on HPVHNSCC specific epigenetic alterations combined with high risk HPV DNA presence has potential as useful test for presence of HPVHNSCC. This project will serve as a discovery and diagnostic validation biomarker development trial for HPVHNSCC detection with potential application for assessment of disease response and development of a population based screening test.